The effects of alteplase 3 to 6 hours after stroke in the epithet-defuse combined dataset: Post Hoc case-control study

Stroke

Volumn 44, Issue 1, 2013, Pages 87-93

  Ogata, Toshiyasu ^a   Christensen, Soren ^b   Nagakane, Yoshinari ^a   Ma, Henry ^a,d   Campbell, Bruce C V ^b,c   Churilov, Leonid ^a,b   Lansberg, Maarten G ^e   Straka, Matus ^f   De Silva, Deidre A ^g   Mlynash, Michael ^e   Bammer, Roland ^f   Olivot, Jean Marc ^e   Desmond, Patricia M ^b,c   Albers, Gregory W ^e   Davis, Stephen M ^b,c   Donnan, Geoffrey A ^a,b  

^a FLOREY INSTITUTE OF NEUROSCIENCE AND MENTAL HEALTH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL MELBOURNE HOSPITAL   (Australia)

^d MONASH UNIVERSITY   (Australia)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f STANFORD UNIVERSITY   (United States)

^g NATIONAL NEUROSCIENCE INSTITUTE   (Singapore)

Author keywords

diffusion weighted image; intravenous tissue plasminogen activator; MR mismatch; perfusion weighted image

Indexed keywords

ALTEPLASE; PLACEBO;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN INFARCTION; BRAIN INFARCTION SIZE; BRAIN PERFUSION; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HUMAN; MAGNETIC RESONANCE ANGIOGRAPHY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERFUSION WEIGHTED IMAGING; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECANALIZATION; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; DATABASES, FACTUAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; STROKE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME;

EID: 84872081602     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.112.668301     Document Type: Article

References (29)

1. Group TNIoNDaSr-PSS. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
2. Wahlgren N, Ahmed N, Dávalos A, Ford GA, Grond M, Hacke W, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369:275-282.
3. Hacke W, Kaste M, Bluhmki E, Brozman M, Dávalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4. 5 hours after acute ischemic stroke. N Engl J Med. 2008;359:1317-1329.
4. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768-774.
5. Donnan GA, Baron JC, Ma H, Davis SM. Penumbral selection of patients for trials of acute stroke therapy. Lancet Neurol. 2009;8:261-269.
6. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7:299-309.
7. Ma H, Zavala JA, Teoh H, Churilov L, Gunawan M, Ly J, et al. Penumbral mismatch is underestimated using standard volumetric methods and this is exacerbated with time. J Neurol Neurosurg Psychiatr. 2009;80:991-996.
8. Nagakane Y, Christensen S, Brekenfeld C, Ma H, Churilov L, Parsons MW, et al. EPITHET: positive result after reanalysis using baseline diffusion-weighted imaging/perfusion-weighted imaging co-registration. Stroke. 2011;42:59-64.
9. Olivot JM, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, et al. Optimal Tmax threshold for predicting penumbral tissue in acute stroke. Stroke. 2009;40:469-475.
10. Zaro-Weber O, Moeller-Hartmann W, Heiss WD, Sobesky J. Maps of time to maximum and time to peak for mismatch definition in clinical stroke studies validated with positron emission tomography. Stroke. 2010;41:2817-2821.
11. Takasawa M, Jones PS, Guadagno JV, Christensen S, Fryer TD, Harding S, et al. How reliable is perfusion MR in acute stroke? Validation and determination of the penumbra threshold against quantitative PET. Stroke. 2008;39:870-877.
12. Albers GW, Thijs VN, Wechsler L, Kemp S, Schlaug G, Skalabrin E, et al. Magnetic resonance imaging profiles predict clinical response to early reperfusion: the diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study. Ann Neurol. 2006;60:508-517.
13. Ogata T, Nagakane Y, Christensen S, Ma H, Campbell BC, Churilov L, et al. A topographic study of the evolution of the MR DWI/PWI mismatch pattern and its clinical impact: a study by the EPITHET and DEFUSE Investigators. Stroke. 2011;42:1596-1601.
14. Lansberg MG, Lee J, Christensen S, Straka M, De Silva DA, Mlynash M, et al. RAPID automated patient selection for reperfusion therapy: a pooled analysis of the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET) and the Diffusion and Perfusion Imaging Evaluation for Understanding Stroke Evolution (DEFUSE) Study. Stroke. 2011;42:1608-1614.
15. Ebinger M, Christensen S, De Silva DA, Parsons MW, Levi CR, Butcher KS, et al. Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point. Stroke. 2009;40:1353-1358.
16. Marks MP, Olivot JM, Kemp S, Lansberg MG, Bammer R, Wechsler LR, et al. Patients with acute stroke treated with intravenous tPA 3-6 hours after stroke onset: correlations between MR angiography findings and perfusion-and diffusion-weighted imaging in the DEFUSE study. Radiology. 2008;249:614-623.
17. Olivot JM, Mlynash M, Thijs VN, Kemp S, Lansberg MG, Wechsler L, et al. Relationships between infarct growth, clinical outcome, and early recanalization in diffusion and perfusion imaging for understanding stroke evolution (DEFUSE). Stroke. 2008;39:2257-2263.
18. Lees KR, Bluhmki E, von Kummer R, Brott TG, Toni D, Grotta JC, et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375:1695-1703.
19. Kakuda W, Lansberg MG, Thijs VN, Kemp SM, Bammer R, Wechsler LR, et al. Optimal definition for PWI/DWI mismatch in acute ischemic stroke patients. J Cereb Blood Flow Metab. 2008;28:887-891.
20. Toth G, Albers GW. Use of MRI to estimate the therapeutic window in acute stroke: is perfusion-weighted imaging/diffusion-weighted imaging mismatch an EPITHET for salvageable ischemic brain tissue? Stroke. 2009;40:333-335.
21. Straka M, Albers GW, Bammer R. Real-time diffusion-perfusion mismatch analysis in acute stroke. J Magn Reson Imaging. 2010;32:1024-1037.
22. Parsons MW, Barber PA, Chalk J, Darby DG, Rose S, Desmond PM, et al. Diffusion-and perfusion-weighted MRI response to thrombolysis in stroke. Ann Neurol. 2002;51:28-37.
23. Schellinger PD, Jansen O, Fiebach JB, Heiland S, Steiner T, Schwab S, et al. Monitoring intravenous recombinant tissue plasminogen activator thrombolysis for acute ischemic stroke with diffusion and perfusion MRI. Stroke. 2000;31:1318-1328.
24. Schellinger PD, Fiebach JB, Jansen O, Ringleb PA, Mohr A, Steiner T, et al. Stroke magnetic resonance imaging within 6 hours after onset of hyperacute cerebral ischemia. Ann Neurol. 2001;49:460-469.
25. The NINDS t-PA Stroke Study Group. Generalized efficacy of t-pa for acute stroke. Subgroup analysis of the NINDS t-pa Stroke Trial. Stroke. 1997;28:2119-2125.
26. Campbell BC, Christensen S, Butcher KS, Gordon I, Parsons MW, Desmond PM, et al. Regional very low cerebral blood volume predicts hemorrhagic transformation better than diffusion-weighted imaging volume and thresholded apparent diffusion coefficient in acute ischemic stroke. Stroke. 2010;41:82-88.
27. Ma H, Parsons MW, Christensen S, Campbell BC, Churilov L, Connelly A, et al. A multicentre, randomized, double-blinded, placebo-controlled Phase III study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits (EXTEND). Int J Stroke. 2012;7:74-80.
28. Efficacy and safety study of desmoteplase to treat acute ischemic stroke. Available at http://www.strokecenter. org/trials/trialDetailaspx?tid= 961&search
29. Qureshi AI, Kirmani JF, Sayed MA, Safdar A, Ahmed S, Ferguson R, et al. Time to hospital arrival, use of thrombolytics, and in-hospital outcomes in ischemic stroke. Neurology. 2005;64:2115-2120.